Therapeutic Response

ERBB2 amplification status confers therapeutic sensitivity to Trastuzumab deruxtecan in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Enhertu (trastuzumab deruxtecan) [product information]. EMA. The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have an activating HER2 (ERBB2) variant and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.